Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

Ítems similars

• The function of orthologues of the human Parkinson’s disease gene LRRK2 across species: implications for disease modeling in preclinical research
  per: Langston, Rebekah G., et al.
  Publicat: (2016)
• LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
  per: Taymans, Jean-Marc, et al.
  Publicat: (2016)
• Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic Implications
  per: Rudenko, Iakov N., et al.
  Publicat: (2014)
• The G2385R risk factor for Parkinson’s disease enhances CHIP-dependent intracellular degradation of LRRK2
  per: Rudenko, Iakov N., et al.
  Publicat: (2017)
• The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease
  per: Cookson, Mark R.
  Publicat: (2010)